Project Grant W81XWH1910295

This Project Grant award of $254,478 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 Allergy and Infectious Diseases Research) supports research to determine the mechanism of resistance for lead peptide-phosphorodiamidate morpholino oligomer (PPMO) compounds against the bacterial pathogens Klebsiella pneumoniae, Acinetobacter baumannii, and Burkholderia cepacia complex. PPMOs are a new class of antibacterial compounds that have shown promise in killing a variety of...

This $451,000 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855) aims to identify new molecular targets for antimicrobial agents against the gram-negative bacterial pathogens Burkholderia pseudomallei and Pseudomonas aeruginosa. The research approach utilizes chemical synthetic lethality, whereby subinhibitory doses of antibiotics are used to expose vulnerabilities...

This federal Project Grant award from the National Institute of General Medical Sciences (NIGMS), under the Biomedical Research and Research Training program (CFDA 93.859), provides $448,250.00 to The Research Foundation For The State University Of New York (operating as Upstate Medical Center) to develop sulfonium lipid nanoparticles as a novel platform for mRNA delivery. The key objectives of this project are to: 1) expand the chemical diversity of sulfonium lipids by incorporating novel...

Novobiotic Pharmaceuticals, LLC received a $4.5 million Project Grant award from the Defense Health Agency to conduct late-stage preclinical development of the antibiotic teixobactin through April 2026. The funding supports research under the Military Medical Research and Development program, which aims to develop medical solutions for battlefield injuries and infectious diseases. Specifically, the award will allow Novobiotic to advance teixobactin, initially discovered using its iChip...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $474,363.00 to Rowan University to develop novel antimicrobial peptides inspired by the clinically approved compound daptomycin. The goal is to create new peptide molecules that mimic daptomycin's key mechanisms of action, such as calcium binding and lipid membrane disruption, while improving resistance to...

This $392,634 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to further develop a novel nanoimmunotherapeutic approach to combat multidrug-resistant (MDR) bacterial infections. The key objectives are to design, fabricate, characterize, and optimize a red blood cell membrane-coated, hemoglobin-encapsulating nanoparticle (RHNP) that can sensitize bacteria to host oxidant...

This Project Grant award, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to optimize a novel antimicrobial peptide called A4-X7 for pulmonary delivery to treat respiratory infections caused by antibiotic-resistant bacterial pathogens, also known as ESKAPE superbugs. The $184,375 award supports research to prepare, characterize, and evaluate the antimicrobial and antibiofilm activities of...

This Project Grant, awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), aims to develop new chemical probes to explore the use of complement recruitment as a strategy for eliminating antibiotic-resistant bacterial pathogens, particularly Pseudomonas aeruginosa. The $407,156 award, with a period of performance from Jul 1, 2025 to Jun 30, 2027, will fund two key research efforts: 1)...

This Project Grant award, totaling $426,875.00, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855). The award supports research to develop a novel, water-soluble, cationic bolaamphiphile (CAB) platform nanocarrier complexed with an antisense oligonucleotide (ASO) targeting the essential Clostridioides difficile DnaE gene. Preliminary studies have shown this DnaE*964 nanocomplex...

This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $275,000 aims to develop a platform for detecting genetic antibiotic resistance motifs that can predict current and future susceptibility to therapeutics. The project will establish the feasibility of leveraging mutational signatures in bacterial DNA to identify antibiotic resistance status, including the potential for rapid development of multi-drug resistance. This approach...